S&P 500   4,244.35 (-0.68%)
DOW   33,334.24 (-0.85%)
QQQ   352.50 (-0.48%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
S&P 500   4,244.35 (-0.68%)
DOW   33,334.24 (-0.85%)
QQQ   352.50 (-0.48%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
S&P 500   4,244.35 (-0.68%)
DOW   33,334.24 (-0.85%)
QQQ   352.50 (-0.48%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
S&P 500   4,244.35 (-0.68%)
DOW   33,334.24 (-0.85%)
QQQ   352.50 (-0.48%)
AAPL   169.56 (-1.40%)
MSFT   310.82 (-0.42%)
META   298.27 (-0.23%)
GOOGL   129.38 (+0.63%)
AMZN   124.81 (-0.93%)
TSLA   235.19 (-3.66%)
NVDA   417.89 (-0.29%)
NIO   8.33 (-0.95%)
BABA   85.51 (-0.47%)
AMD   97.01 (+1.09%)
T   14.85 (-1.13%)
F   12.30 (-1.05%)
MU   67.12 (-1.21%)
CGC   0.86 (-6.73%)
GE   110.69 (+0.69%)
DIS   79.26 (-0.99%)
AMC   7.72 (-2.40%)
PFE   31.93 (-1.45%)
PYPL   56.88 (-3.48%)
NFLX   377.25 (-0.53%)
NASDAQ:PASG

Passage Bio (PASG) Stock Forecast, Price & News

$0.67
-0.01 (-0.87%)
(As of 12:46 PM ET)
Compare
Today's Range
$0.66
▼
$0.69
50-Day Range
$0.67
▼
$1.01
52-Week Range
$0.65
▼
$1.92
Volume
82,013 shs
Average Volume
197,478 shs
Market Capitalization
$36.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.40
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Passage Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,143.2% Upside
$8.40 Price Target
Short Interest
Healthy
0.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Passage Bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$518,601 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.01) to ($1.00) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

124th out of 963 stocks

Biological Products, Except Diagnostic Industry

14th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

PASG stock logo

About Passage Bio (NASDAQ:PASG) Stock

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

PASG Price History

PASG Stock News Headlines

September 25, 2023 | benzinga.com
Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference
September 25, 2023 | finance.yahoo.com
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 5, 2023 | finance.yahoo.com
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
August 11, 2023 | finance.yahoo.com
Lab Notes: Almac Group starts work on $65M Montco expansion expected to create 355 jobs
August 9, 2023 | nasdaq.com
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation
August 7, 2023 | fr.investing.com
Le BPA de Passage Bio a dépassé les attentes de 0,03$, le CA conforme aux prévisions
August 7, 2023 | seekingalpha.com
Passage Bio GAAP EPS of -$0.44 beats by $0.03
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 7, 2023 | finance.yahoo.com
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
August 7, 2023 | finance.yahoo.com
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
July 31, 2023 | finance.yahoo.com
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
July 30, 2023 | finance.yahoo.com
Passage Bio, Inc. (PASG) stock forecast and price target
July 24, 2023 | bizjournals.com
Passage Bio reduces staff by 26% in latest round of job cuts
July 6, 2023 | msn.com
Passage Bio (PASG) Price Target Increased by 12.09% to 8.33
June 30, 2023 | benzinga.com
Passage Bio 10% Owner Trades Company's Stock
June 30, 2023 | benzinga.com
Passage Bio And 2 Other Penny Stocks Insiders Are Aggressively Buying
June 10, 2023 | finance.yahoo.com
PASG - Passage Bio, Inc.
June 5, 2023 | finance.yahoo.com
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
May 19, 2023 | seekingalpha.com
PASG Passage Bio, Inc.
May 12, 2023 | msn.com
Raymond James Maintains Passage Bio (PASG) Outperform Recommendation
May 12, 2023 | msn.com
Recap: Passage Bio Q1 Earnings
May 11, 2023 | fr.investing.com
Le BPA de Passage Bio a manqué les attentes de 0,11$, le CA conforme aux prévisions
May 11, 2023 | markets.businessinsider.com
Goldman Sachs Reaffirms Their Hold Rating on Passage Bio (PASG)
May 11, 2023 | finance.yahoo.com
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
May 4, 2023 | finance.yahoo.com
Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award
April 17, 2023 | benzinga.com
Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
See More Headlines
Receive PASG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter.

PASG Company Calendar

Last Earnings
8/07/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PASG
CUSIP
N/A
CIK
1787297
Web
www.passagebio.com
Phone
267-866-0311
Fax
N/A
Employees
85
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.40
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,143.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-136,130,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-60.01%
Return on Assets
-48.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.73
Quick Ratio
7.73

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.69 per share
Price / Book
0.18

Miscellaneous

Outstanding Shares
54,810,000
Free Float
47,083,000
Market Cap
$37.04 million
Optionable
Not Optionable
Beta
1.00
10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. William Chou M.D. (Age 50)
    Pres, CEO & Director
    Comp: $395.43k
  • Mr. Edgar B. Cale Esq. (Age 59)
    J.D., Gen. Counsel & Company Sec.
    Comp: $674.36k
  • Dr. James M. Wilson M.D. (Age 68)
    Ph.D., Co-Founder & Chief Scientific Advisor
  • Ms. Kathleen Borthwick (Age 47)
    Sr. VP of Fin., Principal Accounting Officer & Interim CFO
  • Mr. Stuart M. Henderson
    Sr. VP of Corp. Devel. & Investor Relations
  • Gregory Fuest
    VP of Global Commercial Strategy & Marketing
  • Dr. Mark Forman M.D. (Age 59)
    Ph.D., Chief Medical Officer
  • Dr. Desiree Luthman D.D.S.
    Sr. VP of Global Regulatory Affairs
  • Eden Fucci
    Sr. VP of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PASG Stock - Frequently Asked Questions

Should I buy or sell Passage Bio stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PASG shares.
View PASG analyst ratings or view top-rated stocks.

What is Passage Bio's stock price forecast for 2023?

5 brokers have issued 1-year price targets for Passage Bio's stock. Their PASG share price forecasts range from $5.00 to $11.00. On average, they predict the company's stock price to reach $8.40 in the next year. This suggests a possible upside of 1,143.2% from the stock's current price.
View analysts price targets for PASG or view top-rated stocks among Wall Street analysts.

How have PASG shares performed in 2023?

Passage Bio's stock was trading at $1.38 on January 1st, 2023. Since then, PASG stock has decreased by 51.0% and is now trading at $0.6757.
View the best growth stocks for 2023 here.

When is Passage Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our PASG earnings forecast.

How were Passage Bio's earnings last quarter?

Passage Bio, Inc. (NASDAQ:PASG) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.03.

What other stocks do shareholders of Passage Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX), Gossamer Bio (GOSS), JD.com (JD), Micron Technology (MU) and Black Diamond Therapeutics (BDTX).

When did Passage Bio IPO?

(PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Chardan was co-manager.

What is Passage Bio's stock symbol?

Passage Bio trades on the NASDAQ under the ticker symbol "PASG."

Who are Passage Bio's major shareholders?

Passage Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include BML Capital Management LLC (3.77%), Renaissance Technologies LLC (1.79%), RBF Capital LLC (0.26%), Pale Fire Capital SE (0.18%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Alexandros Fotopoulos, Bruce A Goldsmith, Gary Romano, Jill M Quigley, Orbimed Advisors Llc, Richard Steven Morris, Sandip Kapadia and Simona King.
View institutional ownership trends.

How do I buy shares of Passage Bio?

Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Passage Bio's stock price today?

One share of PASG stock can currently be purchased for approximately $0.68.

How much money does Passage Bio make?

Passage Bio (NASDAQ:PASG) has a market capitalization of $37.04 million. The company earns $-136,130,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

How can I contact Passage Bio?

Passage Bio's mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The official website for the company is www.passagebio.com. The company can be reached via phone at 267-866-0311 or via email at investors@passagebio.com.

This page (NASDAQ:PASG) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -